A First-in-Class, Brain-Penetrant Small Molecule Inhibitor of the NOS1AP-Tau Interaction Rescues Tau Pathology In Vivo and Improves Cognition
In the authors' words
NOS1AP is a genetically validated driver of tau pathology in Alzheimer's disease (AD), yet the NOS1AP-tau interaction itself has remained pharmacologically untargeted. We report CAPTOR-1, a first-in-class small molecule that disrupts this interaction by binding a pocket in the N-terminal region of NOS1AP (residues 1-126). A drug-resistant NOS1AP Y16A/F42A variant that retained tau binding but exhibited a 78-fold reduction in CAPTOR-1 affinity provides genetic evidence supporting an on-target mechanism. In human iPSC-derived neurons, CAPTOR-1 dose-dependently reduces endogenous NOS1AP-tau association, tau seeding activity, and pathogenic tau phosphorylation, phenocopying genetic NOS1AP knockdown; these effects extend to neurons from patients with sporadic AD. Orally dosed CAPTOR-1 crosses the blood-brain barrier and engages NOS1AP in brain dose-dependently. Chronic oral dosing rescues pathology, synaptic function, and memory in a tauopathy model (PS19) and an amyloidosis model (APP/PS1), sparing wild-type littermates in both. This work establishes pharmacological disruption of the NOS1AP-tau interaction as a viable, disease-modifying strategy for AD and positions CAPTOR-1 as a biomarker-ready chemical probe (pTau217, neurofilament light) for translational studies.
In plain words AI summary
The researchers developed CAPTOR-1, a small molecule that blocks the interaction between two proteins called NOS1AP and tau. In lab-grown human neurons, CAPTOR-1 reduced harmful tau buildup and abnormal tau changes, matching what happens when NOS1AP is genetically removed. When given by mouth, the drug enters the brain and reduces disease signs in two mouse models of Alzheimer's disease. The authors state this work shows that blocking the NOS1AP-tau interaction is a viable approach to treat Alzheimer's disease.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Thursday, October 8. bioRxiv. Preprint, not yet peer-reviewed.